Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies. / Heftdal, Line Dam; Hamm, Sebastian Rask; Pérez-Alós, Laura; Madsen, Johannes Roth; Armenteros, Jose Juan Almagro; Fogh, Kamille; Kronborg, Christoffer Cronwald; Vallentin, Anders Pommer; Hasselbalch, Rasmus Bo; Møller, Dina Leth; Hansen, Cecilie Bo; Pries-Heje, Mia; Gang, Anne Ortved; Ostrowski, Sisse Rye; Frikke-Schmidt, Ruth; Sørensen, Erik; Hilsted, Linda; Bundgaard, Henning; Iversen, Kasper; Garred, Peter; Nielsen, Susanne Dam; Grønbæk, Kirsten.
In: European Journal of Haematology, Vol. 111, No. 2, 2023, p. 229-239.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
AU - Heftdal, Line Dam
AU - Hamm, Sebastian Rask
AU - Pérez-Alós, Laura
AU - Madsen, Johannes Roth
AU - Armenteros, Jose Juan Almagro
AU - Fogh, Kamille
AU - Kronborg, Christoffer Cronwald
AU - Vallentin, Anders Pommer
AU - Hasselbalch, Rasmus Bo
AU - Møller, Dina Leth
AU - Hansen, Cecilie Bo
AU - Pries-Heje, Mia
AU - Gang, Anne Ortved
AU - Ostrowski, Sisse Rye
AU - Frikke-Schmidt, Ruth
AU - Sørensen, Erik
AU - Hilsted, Linda
AU - Bundgaard, Henning
AU - Iversen, Kasper
AU - Garred, Peter
AU - Nielsen, Susanne Dam
AU - Grønbæk, Kirsten
N1 - Publisher Copyright: © 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2023
Y1 - 2023
N2 - Objectives: Initial responses to coronavirus disease 2019 vaccination are impaired in patients with hematological malignancies. We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination. Methods: In 407 hematological patients (45 myeloid, 362 lymphoid) and 98 matched controls, we measured immunoglobulin G (IgG) and neutralizing antibodies specific for the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline, 3 weeks, 2, 6, and 12 months, and interferon-γ release at 12 months. Results: In patients with lymphoid malignancies, SARS-CoV-2 receptor-binding domain IgG concentration and mean neutralizing capacity was lower than in controls at all time points. A diagnosis of chronic lymphocytic B-cell leukemia (CLL) or lymphoma was associated with humoral nonresponse at 12 months compared to having multiple myeloma/amyloidosis (p <.001 and p =.013). Compared to controls, patients with lymphoid malignancies had increased risk of cellular nonresponse. A lymphoma diagnosis was associated with lower risk of cellular nonresponse compared to patients with multiple myeloma/amyloidosis, while patients with CLL had comparable response rates to patients with multiple myeloma/amyloidosis (p =.037 and p =.280). Conclusions: In conclusion, long-term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies.
AB - Objectives: Initial responses to coronavirus disease 2019 vaccination are impaired in patients with hematological malignancies. We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination. Methods: In 407 hematological patients (45 myeloid, 362 lymphoid) and 98 matched controls, we measured immunoglobulin G (IgG) and neutralizing antibodies specific for the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline, 3 weeks, 2, 6, and 12 months, and interferon-γ release at 12 months. Results: In patients with lymphoid malignancies, SARS-CoV-2 receptor-binding domain IgG concentration and mean neutralizing capacity was lower than in controls at all time points. A diagnosis of chronic lymphocytic B-cell leukemia (CLL) or lymphoma was associated with humoral nonresponse at 12 months compared to having multiple myeloma/amyloidosis (p <.001 and p =.013). Compared to controls, patients with lymphoid malignancies had increased risk of cellular nonresponse. A lymphoma diagnosis was associated with lower risk of cellular nonresponse compared to patients with multiple myeloma/amyloidosis, while patients with CLL had comparable response rates to patients with multiple myeloma/amyloidosis (p =.037 and p =.280). Conclusions: In conclusion, long-term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies.
KW - BNT162b2
KW - booster dose
KW - cellular immune response
KW - humoral immune response
KW - lymphoid malignancies
KW - myeloid malignancies
U2 - 10.1111/ejh.13986
DO - 10.1111/ejh.13986
M3 - Journal article
C2 - 37151174
AN - SCOPUS:85158135740
VL - 111
SP - 229
EP - 239
JO - Scandinavian Journal of Haematology
JF - Scandinavian Journal of Haematology
SN - 0902-4441
IS - 2
ER -
ID: 357049639